<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402896</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0929</org_study_id>
    <secondary_id>NCI-2012-02082</secondary_id>
    <secondary_id>W81XWH-05-2-0027</secondary_id>
    <nct_id>NCT00402896</nct_id>
  </id_info>
  <brief_title>Malignant Pleural Effusion With ZD6474</brief_title>
  <official_title>Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn the effect of ZD6474 on the amount of&#xD;
      time between placement of an indwelling pleural catheter and the catheter's removal in&#xD;
      patients with malignant pleural effusion.&#xD;
&#xD;
      This study will also look at the effect that ZD6474 has on tumor cells, biological&#xD;
      characteristics of cells in the body, rate of fluid build-up around the lungs, tumor size,&#xD;
      and thickness of blood vessels. The effect that this drug has on quality of life and&#xD;
      shortness of breath will also be examined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ZD6474 is an investigational drug that has not yet received approval from the FDA. ZD6474 is&#xD;
      designed to limit VEGF. Vascular endothelial growth factor (VEGF) is considered to play a key&#xD;
      role in the development of pleural effusion. Pleural effusion is an abnormal collection of&#xD;
      pleural fluid in the pleural lining surrounding the lungs. The pleural lining is the thin&#xD;
      covering that protects and cushions the lungs. It is made up of two layers of tissue that are&#xD;
      separated by a small amount of fluid.&#xD;
&#xD;
      ZD6474 has shown promising activity against a number of cancers in laboratory tests in&#xD;
      animals with cancer and in some early clinical trials in patients with non-small cell lung&#xD;
      cancer (NSCLC). ZD6474 has also demonstrated significant reduction in pleural effusion in&#xD;
      association with VEGF inhibition of tumor cells in mice with lung tumors and pleural&#xD;
      effusion. It is hoped that ZD6474 will decrease the amount of pleural effusion that occurs in&#xD;
      NSCLC patients. In addition, ZD6474 is thought to block the formation of new blood vessels,&#xD;
      which may limit new blood vessel growth in the tumor and &quot;starve&quot; the tumor.&#xD;
&#xD;
      Before you can start treatment on this study, you will have &quot;screening tests.&quot; These tests&#xD;
      will help the doctor decide if you are eligible to take part in this study. You will have a&#xD;
      complete physical exam, including measurement of vital signs (blood pressure, heart rate,&#xD;
      temperature, and breathing rate), height, and weight. You will be asked questions about your&#xD;
      ability to perform daily activities (performance status evaluation). You will have blood&#xD;
      (about 2-3 teaspoons) drawn for routine tests. You may have up to 3 electrocardiograms (ECG&#xD;
      --a test that measures the electrical activity of the heart). You will also have a chest&#xD;
      x-ray and computed tomography (CT) scans of your chest to measure the status of the disease.&#xD;
      You will be asked to fill out 2 questionnaires about the quality of your life and shortness&#xD;
      of breath. The questionnaires will take about 10-15 minutes, total, to complete. Women who&#xD;
      are able to have children must have a negative blood (about 1-2 teaspoons) pregnancy test.&#xD;
&#xD;
      If you are found to be eligible to participate in the study, you will have an indwelling&#xD;
      intrapleural catheter placed. You will have to sign a separate consent document before&#xD;
      placement of an indwelling intrapleural catheter can be performed. The pleural fluid will be&#xD;
      collected at each clinic visit. The fluid will be saved and analyzed to answer research&#xD;
      questions that are part of this study. You will also need to drain your pleural fluid&#xD;
      everyday. The research nurse will provide you with instructions on how to drain your daily&#xD;
      pleural fluid and a patient &quot;diary&quot; to take home to record the amount of fluid drained every&#xD;
      day. The study doctor or research nurse will review the diary at each clinic visit.&#xD;
&#xD;
      After placement of the intrapleural catheter (Day 1), you will receive treatment with ZD6474.&#xD;
      Treatment on this study is for 10 weeks. You will take a ZD6474 tablet by mouth each morning.&#xD;
      The tablet should not be chewed, crushed, or divided, and should be taken with 8 ounces of&#xD;
      water. You should take the tablet at about the same time every day.&#xD;
&#xD;
      During your participation on this study, you will have a physical exam, routine blood tests&#xD;
      and chest x-ray at Weeks 2, 6, and 10. At Weeks 6 and 10, you will also have a CT scan. You&#xD;
      will have an ECG at Weeks 1, 2, 4, and 8. Your doctor may decide to have additional ECGs to&#xD;
      monitor your condition or if you experience a heart rate of less than 50 at any time during&#xD;
      study participation. You will also be asked to complete 2 questionnaires about the quality of&#xD;
      your life and any shortness of breath you are experiencing. You will complete these&#xD;
      questionnaires at home and return them to the research staff at each clinic visit. You will&#xD;
      be asked to record your weekly blood pressure for the first 6 weeks of study treatment. The&#xD;
      study doctor or research nurse will review the log at each clinic visit.&#xD;
&#xD;
      If you are benefitting from the study treatment and your doctor feels that it is your best&#xD;
      interest, you may continue to receive the study drug longer than 10 weeks. During your&#xD;
      participation in this extended treatment phase, every 4 weeks you will have a physical exam&#xD;
      and your performance status will be evaluated. You will have blood (about 2-3 teaspoons)&#xD;
      drawn for routine tests. Every 4 weeks, you will have ECGs performed. You will also have a&#xD;
      chest x-ray and computed tomography (CT) scans of your chest to measure the status of the&#xD;
      disease every 8 weeks. Your study drug will continue to be provided to you.&#xD;
&#xD;
      You may be taken off study early if you have intolerable side effects or the disease gets&#xD;
      worse.&#xD;
&#xD;
      This is an investigational study. ZD6474, the investigational drug to be used in this study,&#xD;
      is not approved by the FDA for commercial use; however, the FDA has permitted its use in this&#xD;
      research study. Up to 25 patients will take part in this study. All will be enrolled at M. D.&#xD;
      Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Pleurodesis</measure>
    <time_frame>Time from initiation of treatment and catheter insertion up to a maximum of 10 weeks</time_frame>
    <description>Time to pleurodesis from initiation of treatment to catheter removal as measure of pleural effusion Improvement (amount of pleural fluid drainage) where objective was to examine whether ZD6474 would help participants to improve the condition of pleural effusion, and thus remove the catheter earlier. Cox model analysis applied to examine the effect of covariates on the time to catheter removal.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>ZD6474</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg/day orally for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
    <description>300 mg/day orally for 10 weeks.</description>
    <arm_group_label>ZD6474</arm_group_label>
    <other_name>Vascular Endothelial Growth Factor Receptor</other_name>
    <other_name>Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with pleural effusion requiring placement of an indwelling intrapleural&#xD;
             denver catheter for recurrent symptomatic malignant pleural effusion&#xD;
&#xD;
          2. Pathologic documentation of NSCLC&#xD;
&#xD;
          3. Performance status 0 to 2 (Eastern Cooperative Oncology Group (ECOG) scale)&#xD;
&#xD;
          4. International Normalized Ratio (INR) &lt;/= 2.5&#xD;
&#xD;
          5. Signed informed consent prior to any study related procedures&#xD;
&#xD;
          6. Subject must be female or male age 18 years or over&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy or other anticancer therapy in the 3 weeks prior to study. Palliative&#xD;
             radiotherapy will be allowed to extra thoracic sites 2 weeks prior to study&#xD;
&#xD;
          2. No other prior malignancy is allowed except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, or other cancer from which the&#xD;
             patient has been disease-free for at least two years&#xD;
&#xD;
          3. Laboratory results sustained at:Neutrophils less than 1.5x10^9/L or platelets less&#xD;
             than 100x10^9/L; Serum bilirubin &gt;1.5 x the upper limit of reference range&#xD;
             (ULRR);Serum creatinine&gt;1.5xULRR or CrCl &lt;/=30 mL/minute(calculated by Cockcroft-Gault&#xD;
             formula). Potassium,&lt;4.0 mmol despite supplementation;serum calcium (ionized or&#xD;
             adjusted for albumin),or magnesium out of normal range despite supplementation;Alanine&#xD;
             aminotransferase(ALT)or aspartate aminotransferase(AST) &gt; 2.5 x ULRR or alkaline&#xD;
             phosphatase(ALP)&gt; 2.5 x ULRR,or &gt; 5 x ULRR if judged by the investigator to be related&#xD;
             to liver metastases&#xD;
&#xD;
          4. Serious underlying medical condition that would impair the ability of the patient to&#xD;
             receive protocol treatment, specifically cardiac diseases, uncontrolled hypertension&#xD;
             or renal diseases&#xD;
&#xD;
          5. Diagnosis of post-obstructive pneumonia or other serious infection in the 14 days&#xD;
             prior to registration&#xD;
&#xD;
          6. Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          7. Evidence of severe or uncontrolled systemic disease or any concurrent condition which&#xD;
             in the Investigator's opinion makes it undesirable for the patient to participate in&#xD;
             the trial or which would jeopardize compliance with the protocol&#xD;
&#xD;
          8. Clinically significant cardiovascular event such as Myocardial infarction; New York&#xD;
             Heart Association (NYHA) classification of heart disease &gt;/=2 within 3 months before&#xD;
             entry; or presence of cardiac disease that in the opinion of the Investigator increase&#xD;
             the risk of ventricular arrhythmia&#xD;
&#xD;
          9. History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy,&#xD;
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is&#xD;
             symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained&#xD;
             ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded&#xD;
&#xD;
         10. Previous history of corrected QT interval (QTc) prolongation with other medication&#xD;
             that required discontinuation of that medication&#xD;
&#xD;
         11. Congenital long QT syndrome or 1st degree relative with unexplained sudden death under&#xD;
             40 years of age&#xD;
&#xD;
         12. QTc with Bazett's correction that is unmeasurable, or &gt;/=480 msec on screening ECG. If&#xD;
             a patient has QTc &gt;/=480 msec on screening ECG, the screen ECG may be repeated twice&#xD;
             (at least 24 hours apart). The average QTc from the three screening ECGs must be &lt;480&#xD;
             msec in order for the patient to be eligible for the study). Patients who are&#xD;
             receiving a drug that has a risk of QTc prolongation are excluded if QTc is &gt;/= 460&#xD;
             msec&#xD;
&#xD;
         13. Any concomitant medication that may cause QTc prolongation or induce Torsades de&#xD;
             Pointes&#xD;
&#xD;
         14. Hypertension not controlled by medical therapy (systolic blood pressure greater than&#xD;
             160 mm Hg or diastolic blood pressure greater than 100 mm Hg)&#xD;
&#xD;
         15. Women who are currently pregnant or breast feeding&#xD;
&#xD;
         16. Participation in a clinical trial of any investigational agents within 30 days prior&#xD;
             to commencing study treatment&#xD;
&#xD;
         17. In 2nd line or later, the last dose of prior chemotherapy is discontinued less than 3&#xD;
             weeks before the start of study therapy&#xD;
&#xD;
         18. In 2nd line or later, the last radiation therapy discontinued less than 2 weeks before&#xD;
             the start of study therapy except palliative radiotherapy&#xD;
&#xD;
         19. If it is in 2nd line or later, any unresolved toxicity greater than CTC grade 1 from&#xD;
             previous anti-cancer therapy&#xD;
&#xD;
         20. Previous enrollment or randomization of treatment in the present study&#xD;
&#xD;
         21. Patients with pre-existing placement of intrapleural catheter&#xD;
&#xD;
         22. Presence of left bundle branch block (LBBB.)&#xD;
&#xD;
         23. Major surgery within 4 weeks, or incompletely healed surgical incision before starting&#xD;
             study therapy&#xD;
&#xD;
         24. Patients may not have a history of a bleeding diathesis&#xD;
&#xD;
         25. Currently active diarrhea that may affect the ability of the patient to absorb the&#xD;
             ZD6474 or tolerate diarrhea&#xD;
&#xD;
         26. Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin,&#xD;
             carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Jimenez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>September 2, 2015</results_first_submitted>
  <results_first_submitted_qc>February 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2016</results_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Pleural Effusion</keyword>
  <keyword>Indwelling Intrapleural Denver Catheter</keyword>
  <keyword>ZD6474</keyword>
  <keyword>Vascular Endothelial Growth Factor Receptor</keyword>
  <keyword>VEGFR</keyword>
  <keyword>Epidermal Growth factor Receptor</keyword>
  <keyword>EGFR</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 2006 to July 2010 at UT MD Anderson Cancer Center included NSCLC participants diagnosed with proven metastatic disease to the pleural space by pleural fluid cytology or pleural biopsy and required IPC placement because of symptomatic recurrent pleural effusions between May 2007 and February 2010.</recruitment_details>
      <pre_assignment_details>The clinical trial was terminated before reaching the target patient accrual due to ZD6474 unavailability and of the 28 enrolled but only 20 received treatment. Slow accrual was a contributing factor to early termination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZD6474</title>
          <description>300 mg/day orally for 10 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZD6474</title>
          <description>300 mg/day orally for 10 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="46" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Pleurodesis</title>
        <description>Time to pleurodesis from initiation of treatment to catheter removal as measure of pleural effusion Improvement (amount of pleural fluid drainage) where objective was to examine whether ZD6474 would help participants to improve the condition of pleural effusion, and thus remove the catheter earlier. Cox model analysis applied to examine the effect of covariates on the time to catheter removal.</description>
        <time_frame>Time from initiation of treatment and catheter insertion up to a maximum of 10 weeks</time_frame>
        <population>Twenty eligible participants were analyzed for the primary outcome in the trial, eleven completed 10 weeks of treatment. All twenty participants completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>ZD6474</title>
            <description>300 mg/day orally for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Pleurodesis</title>
          <description>Time to pleurodesis from initiation of treatment to catheter removal as measure of pleural effusion Improvement (amount of pleural fluid drainage) where objective was to examine whether ZD6474 would help participants to improve the condition of pleural effusion, and thus remove the catheter earlier. Cox model analysis applied to examine the effect of covariates on the time to catheter removal.</description>
          <population>Twenty eligible participants were analyzed for the primary outcome in the trial, eleven completed 10 weeks of treatment. All twenty participants completed the study.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="15" upper_limit="NA">Distributional assumptions were not available making it not possible to obtain an exact 95% confidence interval for the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection for 10 week treatment period. Collection period: May 2007 to February 2010.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ZD6474</title>
          <description>300 mg/day orally for 10 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>R. Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <description>Transient Ischemic Attack</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Motor Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Left Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>partial thromboplastin time (PTT)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Prolonged PTT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Distension/bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carlos A. Jimenez, MD/Professor, Pulmonary Medicine</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

